174 related articles for article (PubMed ID: 16161048)
1. Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis.
Scott M; McCluggage WG; Hillan KJ; Hall PA; Russell SE
Int J Cancer; 2006 Mar; 118(5):1325-9. PubMed ID: 16161048
[TBL] [Abstract][Full Text] [Related]
2. Altered expression of the septin gene, SEPT9, in ovarian neoplasia.
Burrows JF; Chanduloy S; McIlhatton MA; Nagar H; Yeates K; Donaghy P; Price J; Godwin AK; Johnston PG; Russell SE
J Pathol; 2003 Dec; 201(4):581-8. PubMed ID: 14648661
[TBL] [Abstract][Full Text] [Related]
3. Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours.
Scott M; Hyland PL; McGregor G; Hillan KJ; Russell SE; Hall PA
Oncogene; 2005 Jul; 24(29):4688-700. PubMed ID: 15782116
[TBL] [Abstract][Full Text] [Related]
4. Precursors and pathogenesis of ovarian carcinoma.
Lim D; Oliva E
Pathology; 2013 Apr; 45(3):229-42. PubMed ID: 23478230
[TBL] [Abstract][Full Text] [Related]
5. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
6. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
7. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
8. High SEPT9_v1 expression in human breast cancer cells is associated with oncogenic phenotypes.
Gonzalez ME; Peterson EA; Privette LM; Loffreda-Wren JL; Kalikin LM; Petty EM
Cancer Res; 2007 Sep; 67(18):8554-64. PubMed ID: 17875694
[TBL] [Abstract][Full Text] [Related]
9. [Molecular carcinogenesis of ovarian carcinoma].
Diebold J
Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
[TBL] [Abstract][Full Text] [Related]
10. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
11. DNA Cytometry and Nuclear Morphometry in Ovarian Benign, Borderline and Malignant Tumors.
El Din AA; Badawi MA; Aal SE; Ibrahim NA; Morsy FA; Shaffie NM
Open Access Maced J Med Sci; 2015 Dec; 3(4):537-44. PubMed ID: 27275284
[TBL] [Abstract][Full Text] [Related]
12. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
13. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.
Browne A; Sriraksa R; Guney T; Rama N; Van Noorden S; Curry E; Gabra H; Stronach E; El-Bahrawy M
Cytokine; 2013 Oct; 64(1):413-21. PubMed ID: 23727325
[TBL] [Abstract][Full Text] [Related]
15. Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue.
Connolly D; Hoang HG; Adler E; Tazearslan C; Simmons N; Bernard VV; Castaldi M; Oktay MH; Montagna C
Biol Chem; 2014 Feb; 395(2):157-67. PubMed ID: 24127542
[TBL] [Abstract][Full Text] [Related]
16. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
17. Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridization study.
Boman F; Buisine MP; Wacrenier A; Querleu D; Aubert JP; Porchet N
J Pathol; 2001 Mar; 193(3):339-44. PubMed ID: 11241413
[TBL] [Abstract][Full Text] [Related]
18. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
Vasconcelos I; Darb-Esfahani S; Sehouli J
BJOG; 2016 Mar; 123(4):498-508. PubMed ID: 26705090
[TBL] [Abstract][Full Text] [Related]
19. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
[TBL] [Abstract][Full Text] [Related]
20. Impaired FHIT expression characterizes serous ovarian carcinoma.
Ozaki K; Enomoto T; Yoshino K; Fujita M; Buzard GS; Kawano K; Yamasaki M; Murata Y
Br J Cancer; 2001 Jul; 85(2):247-54. PubMed ID: 11461085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
